Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset

被引：0
作者：
Richard Channick
Kelly M. Chin
Vallerie V. McLaughlin
Matthew R. Lammi
Roham T. Zamanian
Stefano Turricchia
Rose Ong
Lada Mitchell
Nick H. Kim
机构：
[1] University of California,David Geffen School of Medicine
[2] Los Angeles,undefined
[3] UCLA,undefined
[4] UT Southwestern Medical Center,undefined
[5] University of Michigan,undefined
[6] Johns Hopkins School of Medicine,undefined
[7] Stanford University,undefined
[8] Actelion Pharmaceuticals Ltd,undefined
[9] a Johnson & Johnson Company,undefined
[10] Global Medical Affairs,undefined
[11] Actelion Pharmaceuticals Ltd,undefined
[12] a Johnson & Johnson Company,undefined
[13] Global Epidemiology,undefined
[14] Actelion Pharmaceuticals Ltd,undefined
[15] a Johnson & Johnson Company,undefined
[16] Statistics & Decision Sciences-Medical Affairs and Established Products,undefined
[17] University of California,undefined
[18] San Diego,undefined
来源：
Cardiology and Therapy | 2024年 / 13卷
关键词：
Connective tissue disease; Macitentan; Mixed connective tissue disease; Pulmonary arterial hypertension; Real-world evidence; Scleroderma; Systemic lupus erythematosus; Systemic sclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：315 / 339
页数：24
相关论文
共 164 条
[1]  
Gaine S(2017)Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension Eur Respir J 50 1602493-1030
[2]  
Chin K(2018)Pulmonary arterial hypertension associated with connective tissue diseases: a review focusing on distinctive clinical aspects Eur J Clin Invest 173 1023-1117
[3]  
Coghlan G(2006)Pulmonary arterial hypertension in France: results from a national registry Am J Resp Crit Care 192 1111-1054
[4]  
Channick R(2015)Comparison of treatment response in idiopathic and connective tissue disease-associated pulmonary arterial hypertension Am J Resp Crit Care 148 1043-555
[5]  
Di Scala L(2015)Five-year outcomes of patients enrolled in the REVEAL Registry Chest 36 549-1394
[6]  
Galie N(2010)Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension Eur Respir J 138 1383-456
[7]  
Kato M(2010)Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype Chest 142 448-1227
[8]  
Atsumi T(2012)An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry Chest 76 1219-818
[9]  
Humbert M(2017)Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial Ann Rheum Dis 369 809-253
[10]  
Sitbon O(2013)Macitentan and morbidity and mortality in pulmonary arterial hypertension N Engl J Med 15 240-847
12345678910